EISAI CO LTD by Eisai Co., Ltd. (ESALF) Stock Price, Quote, News & History

SPY772.04+0.09%QQQ745.40+0.12%BTC/USD84,492.28+0.07%DIA517.72+0.04%GLD393.05−0.09%TLT79.38+0.08%

EISAI CO LTD by Eisai Co., Ltd. (ESALF) Stock Price, Quote, News & History

ESALFOTCPK

Trade with Public

$31.55

At close: Sep 25, 5:00 PM EST

$26.18

-5.37-17.01%

After Hours: May 22, 9:09 AM EST

OverviewNews Financials Sentiment Compare

Key Statistics

Open

Volume / Avg.

26.00K / 433.00

Day Range

- - -

52 Wk Range

23.88 - 35.83

Market Cap

P/E Ratio

36.32

Dividend Yield

3.21%

Exchange

OTC

RSI

Short Interest

Days to Cover

999.99

Recent Eisai Co., Ltd. News

Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle

CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.

Vandana Singh

Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Vandana Singh

Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement

The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated the drug's benefits are too small to justify the cost for NHS use.

Vandana Singh

Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events

The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards making the treatment available in the EU, where Alzheimer's affects 6.9 million people.

Vandana Singh

Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'

Benzinga Neuro

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

61.32B

Investing Cash Flow (TTM)

-41.80B

Financing Cash Flow (TTM)

-61.10B

Free Cash Flow (TTM)

20.16B

Capital Expenditure (TTM)

-41.17B

Net Change in Cash (TTM)

-41.57B

Valuation Metrics

Enterprise Value

$8.43B

PE Ratio (TTM)

36.32

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

1.70

PB Ratio (TTM)

1.56

Earnings Yield % (TTM)

2.75%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

13.80

Price / EBITDA (TTM)

14.61

Price / Free Cash Flow (TTM)

69.48

Book Value / Share

$20.23

Company Debt

Total Debt

$186.08B

LT Debt

$134.78B

LT Debt Issuance (TTM)

$35.00B

LT Debt Repayment (TTM)

-$35.01B

Total Cash

$245.42B

Debt to Equity

0.21

Issuance of Debt (TTM)

-$9.00M

Repayment of Debt (TTM)

-$35.01B

Key Statistics

Open

Volume / Avg.

26.00K / 433.00

Day Range

- - -

52 Wk Range

23.88 - 35.83

Market Cap

P/E Ratio

36.32

Dividend Yield

3.21%

Exchange

OTC

RSI

Short Interest

Days to Cover

999.99

About

Sector

Health Care

Industry

Pharmaceuticals

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, includ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

FAQ

How do I buy EISAI CO LTD by Eisai Co., Ltd. (ESALF) stock?

You can purchase shares of EISAI CO LTD by Eisai Co., Ltd. (OTCPK:ESALF) through any online brokerage.

View our list of the best stock brokerages

Who are EISAI CO LTD by Eisai Co., Ltd. (ESALF) competitors?

There are no as such competitors for EISAI CO LTD by Eisai Co., Ltd..

What is the forecast, or price target, for EISAI CO LTD by Eisai Co., Ltd. (ESALF) stock?

There is no analysis for EISAI CO LTD by Eisai Co., Ltd. to provide a consensus price target.

What is the current price for EISAI CO LTD by Eisai Co., Ltd. (ESALF)?

The stock price for EISAI CO LTD by Eisai Co., Ltd. (OTCPK: ESALF) is $31.55 last updated September 22, 2026 at 10:14 AM EDT.

Does EISAI CO LTD by Eisai Co., Ltd. (ESALF) pay a dividend?

There are no upcoming dividends for EISAI CO LTD by Eisai Co., Ltd..

When is EISAI CO LTD by Eisai Co., Ltd. (OTCPK:ESALF) reporting earnings?

EISAI CO LTD by Eisai Co., Ltd. does not have any upcoming earnings scheduled.

Is EISAI CO LTD by Eisai Co., Ltd. (ESALF) going to split?

There is no upcoming split for EISAI CO LTD by Eisai Co., Ltd..

What sector and industry does EISAI CO LTD by Eisai Co., Ltd. (ESALF) operate in?

EISAI CO LTD by Eisai Co., Ltd. is in the Health Care sector and Pharmaceuticals industry. They are listed on the OTCPK.